Poseida Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Poseida Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2021 to Q3 2024.
  • Poseida Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 236 %, a 121% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 236 +129 +121% Sep 30, 2024
Q2 2024 205 +115 +127% Jun 30, 2024
Q1 2024 150 +50.9 +51.2% Mar 31, 2024
Q4 2023 125 +18.3 +17.1% Dec 31, 2023
Q3 2023 107 +3.17 +3.06% Sep 30, 2023
Q2 2023 90.5 -16.5 -15.4% Jun 30, 2023
Q1 2023 99.5 +18.7 +23.2% Mar 31, 2023
Q4 2022 107 +45.3 +73.6% Dec 31, 2022
Q3 2022 104 +50.4 +94.6% Sep 30, 2022
Q2 2022 107 +62 +138% Jun 30, 2022
Q1 2022 80.8 +6.61 +8.92% Mar 31, 2022
Q4 2021 61.5 Dec 31, 2021
Q3 2021 53.2 Sep 30, 2021
Q2 2021 45 Jun 30, 2021
Q1 2021 74.2 Mar 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.